Article
Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Journal of translational medicine - 30 Apr 2024
Chen Weihao, Huang Jingtao, Zhao Yeqian, Huang Luo, Yuan Zhiyang, Gu Miner, Xu Xiaojun, Shi Jimin, Luo Yi, Yu Jian, Lai Xiaoyu, Liu Lizhen, Fu Huarui, Bao Chenhui, Huang Xin, Zheng Zhongzheng, Huang He, Hu Xiaoxia, Zhao Yanmin
Abstract excerpt
BACKGROUND: Droplet digital PCR (ddPCR) is widely applied to monitor measurable residual disease (MRD). However, there are limited studies on the feasibility of ddPCR-MRD monitoring after allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially targeting multiple molecular markers simultaneously. METHODS: Our study collected samples from patients with acute myeloid leukemia (AML) or high-risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
